Milligan John F

Gilead Sciences Inc.

President and CEO, Director

Avg. Two Year Performance

18% Avg. Purchase Return 9% Compound

3% Avg. Sale Return 2% Compound

Holdings: 1.57M shares

Last Three Months: 23-Aug-24 -- 22-Nov-24

0 Net Amount

Buy:	0	--
Sell:	0	--

Sentiment

Company Sentiment

Biotechnology

Drugs

Two Year Chart

23-Nov-22 -- 22-Nov-24

Price ($)

Two Year Stock Price Chart

Sentiment

Company Sentiment

Most Recent Insider Transactions